- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05518968
Videoconferencing Acceptance and Commitment Therapy With a Web App Use for Family Caregivers of People With Dementia
January 3, 2024 updated by: Areum Han, University of Alabama at Birmingham
An Eight-week Program for Family Caregivers of People With Dementia Involving Coach-guided Videoconferencing Sessions With the Use of a Web App Based on Acceptance and Commitment Therapy: A Pilot Study
The purpose of the pilot study is to assess the effects of an 8-week program on improving mental health in depressed family caregivers of people with dementia.
The program will involve 8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy (ACT) for 8 weeks.
Also, the study aims to understand these caregivers' experiences in the program, including their perspectives on the app features and contents.
We aim to recruit 8-10 people for this pilot project.
Outcomes regarding caregivers' mental health and ACT processes will be collected at pretest and posttest (after the completion of the 8-week program) and compared over time (i.e., posttest scores compared to pretest).
At posttest, acceptability and perceived usability of the app will be evaluated using the 10-item System Usability Scale and 30-40 minute individual interviews.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The purpose of the pilot study is to assess the effects of an 8-week program on improving mental health in depressed family caregivers of people with dementia.
The program will involve 8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy (ACT) for 8 weeks.
Also, the study aims to understand these caregivers' experiences in the program, including their perspectives on the app features and contents.
We aim to recruit 8-10 people for this pilot project.
Outcomes regarding caregivers' mental health and ACT processes will be collected at pretest and posttest (after the completion of the 8-week program) and compared over time (i.e., posttest scores compared to pretest).
At posttest, acceptability and perceived usability of the app will be evaluated using the 10-item System Usability Scale and 30-40 minute individual interviews.
Participants' characteristics will be summarized using descriptive statistics.
Either the Wilcoxon signed-rank test (a non-parametric test) or the paired sample t-test (a parametric test) will be performed to test the exploratory hypothesis that participants' scores for the outcome measures would significantly improve at posttest compared to pretest.
Because of the exploratory nature of the study, no adjustment of p values will be conducted for multiple statistical comparisons of the outcome measures.
Statistical significance will be set at p <.05, and the effect sizes derived from this pilot study will form a basis for determining a sample size with sufficient statistical power required for a subsequent clinical trial.
Caregivers' experiences in the app use and perspectives on the developed app will be explored using individual Zoom interviews.
Interpretative phenomenological analysis will be used to analyze the interview data.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- community-dwelling adults (age 18 or over) who are currently taking the primary responsibility for the care of a relative with dementia living in the community
- having at least mild depression as measured by the Patient Health Questionnaire (PHQ)-9
- having a web-enabled device (e.g., a smartphone, a tablet, or a laptop/desktop) with the internet access at home
Exclusion Criteria:
- having cognitive, physical, or sensory deficits or language barriers (non-English communicator) that might impede study participation
- receiving a psychological therapy at the time of recruitment
- having a prior experience in acceptance and commitment therapy
- having psychiatric hospitalizations in the previous two years
- considering or planning to place relatives with dementia in a nursing home within 3 months
- recent frequent hospitalizations of their relatives with dementia that might contribute to study dropout
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Acceptance and Commitment Therapy
8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
|
8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline to immediately after the 8-week intervention on the Patient Health Questionnaire-9
Time Frame: Change from baseline to immediately after the 8-week intervention
|
The Patient Health Questionnaire-9 is a 9-item questionnaire assessing depressive symptoms on a scale of 0 to 3. Scores range from 0 to 27.
Higher scores indicate greater symptomatology in depression.
|
Change from baseline to immediately after the 8-week intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline to immediately after the 8-week intervention on the Generalized Anxiety Disorder-7
Time Frame: Change from baseline to immediately after the 8-week intervention
|
The Generalized Anxiety Disorder-7 is a 7-item questionnaire assessing anxiety on a scale of 0 to 3. Scores range from 0 to 21.
Higher scores indicate greater anxiety.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Perceived Stress Scale
Time Frame: Change from baseline to immediately after the 8-week intervention
|
The Perceived Stress Scale is a 10-item questionnaire assessing stress on a scale of 0 to 4. Scores range from 0 to 40.
Higher scores indicate greater stress.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the World Health Organization Quality of Life - Psychological health component
Time Frame: Change from baseline to immediately after the 8-week intervention
|
World Health Organization Quality of Life - Psychological health component has 6 items measuring psychological quality of life on scale of 1 to 5. Scores range from 6 to 30.
Higher scores denote higher quality of life in terms of psychological health.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Zarit Burden Interview
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Zarit Burden Interview is a 12-item self-report questionnaire assessing caregiver burden on a scale of 0 to 4. Higher scores indicate higher levels of burden.
The total scores range from 0 to 48, and scores of 17 or greater indicate severe/high burden.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Marwit-Meuser Caregiver Grief Inventory Brief-Form
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Marwit-Meuser Caregiver Grief Inventory Brief-Form is a 6-item self-report questionnaire assessing grief of caregivers on a scale of 1 to 5. Scores range from 6 to 30.
Higher scores indicate higher levels of grief.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Caregiver Guilt Questionnaire
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Caregiver Guilt Questionnaire is a 22-item self-report questionnaire assessing feelings of guilt in caregivers on a scale of 0 to 4. Scores range from 0 to 88.
Higher scores indicate higher levels of guilt.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Self-Compassion Scale-Short Form
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Self-Compassion Scale- Short Form is a 12-item self-report questionnaire assessing self-compassion on a scale of 1 to 5. Scores range from 12 to 60. Higher scores indicate higher levels of self-compassion.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Action and Acceptance Questionnaire-II
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Action and Acceptance Questionnaire -II is a 7-item self-report questionnaire measuring psychological flexibility on a scale of 1 to 7. Scores range from 7 to 49.
Higher scores indicate poor psychological flexibility.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Cognitive Fusion Questionnaire
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Cognitive Fusion Questionnaire -7 is a 7-item self-report questionnaire measuring cognitive fusion on scale of 1 to 7. Scores range from 7 to 49.
Higher scores indicate greater levels of cognitive fusion.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Engaged Living Scale
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Engaged Living Scale -9 is a 9-item self-assessment instrument that measures clarity and engagement with personal values and life fulfillment on a scale of 1 to 5. The total scores range from 9 to 45, and higher scores indicate increased clarity and engagement with personal values and greater life fulfillment.
|
Change from baseline to immediately after the 8-week intervention
|
|
Change from baseline to immediately after the 8-week intervention on the Five Facet Mindfulness Questionnaire
Time Frame: Change from baseline to immediately after the 8-week intervention
|
Five Facet Mindfulness Questionnaire (FFMQ) is a 39-item self-assessment instrument that measures five aspects of mindfulness (i.e., observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience) on a scale of 1 to 5. The total scores range from 39 to 195, and higher scores indicate greater mindfulness.
|
Change from baseline to immediately after the 8-week intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
System Usability Scale
Time Frame: immediately after the 8-week intervention
|
The System Usability Scale (SUS) is a 10-item self-report questionnaire measuring usability of a tool/program/intervention. Higher scores indicate greater levels of perceived usability of the intervention.
|
immediately after the 8-week intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Areum Han, PhD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2025
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2027
Study Registration Dates
First Submitted
August 25, 2022
First Submitted That Met QC Criteria
August 25, 2022
First Posted (Actual)
August 29, 2022
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 3, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300009858
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
Fondation FondaMentalGYNOVNot yet recruitingDepression | Depression in Adults | Depression DisorderFrance
Clinical Trials on Acceptance and commitment therapy
-
Anne Roche, MACompletedQuality of Life | AgingUnited States
-
Universidade Federal do ParanáActive, not recruitingObsessive-Compulsive DisorderBrazil
-
University of CoimbraUnknown
-
Ataturk UniversityNot yet recruitingChronic Mental DisordersTurkey
-
Universiti Sains MalaysiaRecruitingBreast Cancer FemaleMalaysia
-
University of CyprusNot yet recruitingDepression | Anxiety Disorders | Post Traumatic Stress Disorder
-
University of TromsoThe Royal Norwegian Ministry of HealthCompleted
-
University of NottinghamNottinghamshire Healthcare NHS Foundation Trust; Derbyshire Healthcare NHS...Completed
-
Nova Scotia Health AuthorityCompleted
-
VA Office of Research and DevelopmentCompletedChronic Pain | Mild Traumatic Brain Injury | Distress-based PsychopathologyUnited States